The Message for World Kidney Day 2009: Hypertension and Kidney Disease: a Marriage That Should Be Prevented

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2009 Mar 24

PMID 19302426

Citations 12

Authors

George L Bakris

Eberhard Ritz

Affiliations

Soon will be listed here.

Abstract

The prevalence of chronic kidney disease (CKD) continues to increase worldwide as does end stage renal disease. The most common, but not only, causes of CKD are hypertension and diabetes. CKD is associated with a significant increase in cardiovascular (CV) risk as most patients with CKD die of a CV cause. Moreover, CV risk increases proportionally as estimated glomerular filtration rate falls below 60 mL/min. CV causes of death in CKD are more prevalent than those from cancer; as a result, the identification and reduction of CKD is a public health priority. High blood pressure is a key pathogenic factor that contributes to the deterioration of kidney function. The presence of kidney disease is a common and underappreciated preexisting medical cause of resistant hypertension. Therefore, treatment of hypertension has become the most important intervention in the management of all forms of CKD. For this reason, World Kidney Day on March 12, 2009 will emphasize the role of hypertension.

Citing Articles

Prevalence, awareness, treatment, and control of hypertension based on ACC/AHA versus JNC7 guidelines in the PERSIAN cohort study.

Sepanlou S, Najafi F, Poustchi H, Parsaeian M, Ahmadi A, Somi M Sci Rep. 2022; 12(1):4057.

PMID: 35260709 PMC: 8904851. DOI: 10.1038/s41598-022-07896-9.

Analysing detection of chronic diseases with prolonged sub-clinical periods: modelling and application to hypertension in the U.S.

Brinks R, Kaufmann S, Hoyer A, Gregg E, Saal J BMC Med Res Methodol. 2019; 19(1):213.

PMID: 31775635 PMC: 6880443. DOI: 10.1186/s12874-019-0845-2.

Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study.

Tanaka K, Okada Y, Mori H, Inada Y, Suzuka K, Uriu K Diabetol Int. 2019; 7(4):368-374.

PMID: 30603288 PMC: 6224979. DOI: 10.1007/s13340-016-0258-y.

Fractal properties and morphological investigation of Nano hydrochlorothiazide is used to treat hypertension.

Kazemi Korayem A, Ghamami S, Bahrami Z BMC Pharmacol Toxicol. 2018; 19(1):70.

PMID: 30413182 PMC: 6230244. DOI: 10.1186/s40360-018-0259-5.

High prevalence of hypertension in an agricultural village in Madagascar.

Manus M, Bloomfield G, Sobel Leonard A, Guidera L, Samson D, Nunn C PLoS One. 2018; 13(8):e0201616.

PMID: 30114223 PMC: 6095505. DOI: 10.1371/journal.pone.0201616.

References

Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N . Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007; 117(4):e25-146. DOI: 10.1161/CIRCULATIONAHA.107.187998. View

Alebiosu C, Ayodele O . The global burden of chronic kidney disease and the way forward. Ethn Dis. 2005; 15(3):418-23. View

Perico N, Plata R, Anabaya A, Codreanu I, Schieppati A, Ruggenenti P . Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia. Kidney Int Suppl. 2005; (97):S87-94. DOI: 10.1111/j.1523-1755.2005.09715.x. View

Townsend R . Analyzing the radial pulse waveform: narrowing the gap between blood pressure and outcomes. Curr Opin Nephrol Hypertens. 2007; 16(3):261-6. DOI: 10.1097/MNH.0b013e328042baa4. View

Wen C, Cheng T, Tsai M, Chang Y, Chan H, Tsai S . All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008; 371(9631):2173-82. DOI: 10.1016/S0140-6736(08)60952-6. View

Atkins R . The epidemiology of chronic kidney disease. Kidney Int Suppl. 2005; (94):S14-8. DOI: 10.1111/j.1523-1755.2005.09403.x. View

Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J . Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365(9455):217-23. DOI: 10.1016/S0140-6736(05)17741-1. View

Whelton P, Beevers D, Sonkodi S . Strategies for improvement of awareness, treatment and control of hypertension: results of a panel discussion. J Hum Hypertens. 2004; 18(8):563-5. DOI: 10.1038/sj.jhh.1001738. View

10.

McCullough P, Jurkovitz C, Pergola P, McGill J, Brown W, Collins A . Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007; 167(11):1122-9. DOI: 10.1001/archinte.167.11.1122. View

11.

Ostchega Y, Yoon S, Hughes J, Louis T . Hypertension awareness, treatment, and control--continued disparities in adults: United States, 2005-2006. NCHS Data Brief. 2009; (3):1-8. View

12.

Sarafidis P, Li S, Chen S, Collins A, Brown W, Klag M . Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008; 121(4):332-40. DOI: 10.1016/j.amjmed.2007.11.025. View

13.

Sarafidis P, Bakris G . State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008; 10(2):130-9. PMC: 8110159. DOI: 10.1111/j.1751-7176.2008.07309.x. View

14.

Peterson G, De Backer T, Gabriel A, Ilic V, Vagaonescu T, Appel L . Prevalence and correlates of left ventricular hypertrophy in the African American Study of Kidney Disease Cohort Study. Hypertension. 2007; 50(6):1033-9. DOI: 10.1161/HYPERTENSIONAHA.107.090613. View

15.

Rao M, Qiu Y, Wang C, Bakris G . Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008; 51(4 Suppl 2):S30-7. DOI: 10.1053/j.ajkd.2007.12.012. View